Expression of JAK/STAT Signaling Proteins at Diagnosis and Remission in Patients with Acute Myeloid Leukemia

Overview

Journal Oman Med J

Specialty General Medicine

Date 2024 Nov 5

PMID 39497941

Authors

Safa Al-Amrani

Fahad Al-Zadjali

Yasir Jeelani

Zaaima Al-Jabri

Mahdiya Al-Bulushi

Mohammed AlRawahi

Adhari Al Zaabi

Jalila Alshekaili

Mohammed Al-Huneini

Murtadha Al-Khabori

Affiliations

Soon will be listed here.

Abstract

Objectives: Acute myeloid leukemia (AML), among other malignancies, has been linked to the deregulation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway, which is essential for cell growth, proliferation, and differentiation. This study aimed to investigate the expression of JAK/STAT proteins at diagnosis and remission and how it affects overall survival (OS).

Methods: This is a prospective study conducted in the College of Medicine, Sultan Qaboos University. Using the enzyme-linked immunosorbent assay assay, we estimated the expression levels of JAK/STAT pathway proteins, including pJAK2, pJAK1, JAK1, pSTAT3, pSTAT5, and STAT5, in peripheral blood and bone marrow samples at diagnosis and remission and normalized to the total protein content. Twenty-three adult AML patients (median age = 47) and seven healthy volunteers, who were used as controls, were included in the study. A total of 68 cell lysates were extracted from samples using peripheral blood mononuclear cells isolation assay.

Results: OS was estimated using the Kaplan-Meier curve, and groups were compared with the COX regression model. The overexpression percent was calculated using the chi-square test ( > 0.050). The study revealed that the expression of JAK1, pJAK1, pJAK2, pSTAT3, STAT5, and pSTAT5 in peripheral blood was lower during the diagnosis phase compared to the remission phase ( > 0.050). All these proteins were overexpressed at diagnosis. These proteins did not impact the OS of AML.

Conclusions: The expression levels of these proteins at the time of diagnosis do not significantly influence the OS of patients with AML. The study is limited in sample size and needs to be confirmed in future studies with a larger sample size.

References

Blackburn L, Bender S, Brown S . Acute Leukemia: Diagnosis and Treatment. Semin Oncol Nurs. 2019; 35(6):150950. DOI: 10.1016/j.soncn.2019.150950. View

Khoury J, Medeiros L, Rassidakis G, Yared M, Tsioli P, Leventaki V . Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1):3692-9. View

Benekli M, Xia Z, Donohue K, Ford L, Pixley L, Baer M . Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002; 99(1):252-7. DOI: 10.1182/blood.v99.1.252. View

Steensma D, McClure R, Karp J, Tefferi A, Lasho T, Powell H . JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006; 20(6):971-8. DOI: 10.1038/sj.leu.2404206. View

Boyum A . Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97:77-89. View

Venugopal S, Bar-Natan M, Mascarenhas J . JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. Blood Rev. 2019; 40:100634. DOI: 10.1016/j.blre.2019.100634. View

Kornblau S, Minden M, Rosen D, Putta S, Cohen A, Covey T . Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res. 2010; 16(14):3721-33. PMC: 3385931. DOI: 10.1158/1078-0432.CCR-10-0093. View

Birkenkamp K, Geugien M, Lemmink H, Kruijer W, Vellenga E . Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia. 2001; 15(12):1923-31. DOI: 10.1038/sj.leu.2402317. View

Vainchenker W, Constantinescu S . JAK/STAT signaling in hematological malignancies. Oncogene. 2012; 32(21):2601-13. DOI: 10.1038/onc.2012.347. View

10.

Obermann E, Arber C, Jotterand M, Tichelli A, Hirschmann P, Tzankov A . Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol. 2010; 89(7):663-9. DOI: 10.1007/s00277-009-0890-8. View

11.

Schuringa J, Wierenga A, Kruijer W, Vellenga E . Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000; 95(12):3765-70. View

12.

Cook A, Li L, Ho Y, Lin A, Li L, Stein A . Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood. 2014; 123(18):2826-37. PMC: 4007609. DOI: 10.1182/blood-2013-05-505735. View

13.

De Kouchkovsky I, Abdul-Hay M . 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016; 6(7):e441. PMC: 5030376. DOI: 10.1038/bcj.2016.50. View

14.

Redell M, Ruiz M, Alonzo T, Gerbing R, Tweardy D . Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011; 117(21):5701-9. PMC: 3110027. DOI: 10.1182/blood-2010-04-280123. View

15.

Short N, Rytting M, Cortes J . Acute myeloid leukaemia. Lancet. 2018; 392(10147):593-606. PMC: 10230947. DOI: 10.1016/S0140-6736(18)31041-9. View

16.

Blink M, Buitenkamp T, van den Heuvel-Eibrink M, Danen-van Oorschot A, de Haas V, Reinhardt D . Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011; 25(8):1365-8. DOI: 10.1038/leu.2011.86. View

17.

Ikezoe T, Kojima S, Furihata M, Yang J, Nishioka C, Takeuchi A . Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011; 129(10):2512-21. DOI: 10.1002/ijc.25910. View

18.

Levidou G, Sachanas S, Pangalis G, Kalpadakis C, Yiakoumis X, Moschogiannis M . Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis, Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance. Biomed Res Int. 2014; 2014:251479. PMC: 4026921. DOI: 10.1155/2014/251479. View

19.

Raivola J, Haikarainen T, Abraham B, Silvennoinen O . Janus Kinases in Leukemia. Cancers (Basel). 2021; 13(4). PMC: 7918039. DOI: 10.3390/cancers13040800. View

20.

Xia Z, Sait S, Baer M, Barcos M, Donohue K, Lawrence D . Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res. 2001; 25(6):473-82. DOI: 10.1016/s0145-2126(00)00158-2. View